Robert McKallip, PhD
- BS, Biology, Virginia Tech
- MS, Immunology, Virginia Tech
- PhD, Molecular and Cellular Oncology, The George Washington University
- Postdoctoral Study, Tumor Immunology, Virginia Tech
- Postdoctoral Study, Tumor Immunology, Medical College of Virginia
Dr. McKallip’s laboratory primary focus is on determining the role of CD44 in the regulation of the immune response. Specific projects include; exploring novel strategies to stimulate the immune response to tumors, understanding mechanisms used by tumor cells to escape immune recognition , and destruction as well as exploring the possibility of targeting CD44 isoform expression for the treatment of complication associated with MRSA infections.
- Bentz GL, Lowrey AJ, Horne DC, Nguyen V, Satterfield AR, Ross TD, Harrod AE, Uchakina ON, McKallip RJ. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. PLoS One. 2019 May 24;14(5). PMID: 31125383
- Orr SE, Barnes MC, Joshee L, Uchakina O, McKallip RJ, Bridges CC. Potential mechanisms of cellular injury following exposure to a physiologically relevant species of inorganic mercury. Toxicol Lett. 2019 Apr;304:13-20. doi: 10.1016/j. PMID: 30630035
- Yang LW, Qin DZ, James E, McKallip RJ, Wang NP, Zhang WW, Zheng RH, Han QH, Zhao ZQ. CD44 Deficiency in Mice Protects the Heart Against Angiotensin II-Induced Cardiac Fibrosis. Shock. 2019 Mar;51(3):372-380. PMID: 29470359
- Hostetler BJ, Uchakina ON, Ban H, McKallip RJ#. Treatment of Hematological Malignancies with Glycyrrhizic Acid. Anticancer Res. 2017 Mar;37(3):997-1004. (#Corresponding Author). PMID: 28314257
- Uchakina ON, Ban H, Hostetler BJ, McKallip RJ#. Inhibition of hyaluronic acid formation sensitizes chronic myelogenous leukemia to treatment with doxorubicin. Glycobiology. 2016 Nov;26(11):1171-1179. (#Corresponding Author). PMID 27261196
- Bai F, Pang XF, Zhang LH, Wang NP, McKallip RJ, Garner RE, Zhao ZQ. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis. Life Sci. 2016 May 15;153:141-52. PMID:27085217
- Pang XF, Zhang LH, Bai F, Wang NP, Garner RE, McKallip RJ, Zhao ZQ. Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Des Devel Ther. 2015 Nov 11;9:6043-54. PMID: 26648693
- Ban H, Uchakina O, McKallip RJ#. Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells. Anticancer Res. 2015 Oct;35(10):5231-40. (#Corresponding Author). PMID:26408682
- Zhang L.H., Pang X.F., Bai F, Wang N.P., Shah A.I., McKallip R.J., Li X.W., Wang X, Zhao Z.Q.Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart. Cardiovasc Drugs Ther. 2015 May 21. [Epub ahead of print]. PMID:25994830
- McKallip R.J#., Ban H, Uchakina O.N. Treatment with the hyaluronic Acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation. 2015 Jun;38(3):1250-9. (#Corresponding Author). PMID:25537799
- Immunotherapy of malignant melanoma: Role of CD44 isoforms. Georgia Cancer Coalition Cancer Research Award. McKallip (PI) 04/01/2010-09/30/2011. $50,000.
- The role of CD44 isoforms in immunotherapy of melanoma. NCI/NIH (K22-CA109334). McKallip (PI) 08/01/2006-05/30/2007. $152,927.
- The role of CD44 isoforms in immunotherapy of melanoma. Commonwealth Health Research Fund. McKallip (PI) 2005-2006. $85,770.
- The role of CD44 isoforms in immunotherapy of melanoma. A.D. Williams Fund: McKallip (PI) 2005. $15,000.
- The effects of cannabinoid exposure on tumor growth and the anti-tumor immune response. Jeffress Memorial Trust, McKallip (PI) 2004-2005. $30,000.
- The effects of cannabinoid exposure on tumor growth and the anti-tumor immune response. NIDA Small Grants Program Subaward, McKallip (PI) 2003-2004.$13,000.
- Building Interdisciplinary Research Careers in Womenâ€™s Health (BIRCWH) Scholar. NIH/NIDA K12 DA14041.McKallip (Scholar). Provided salary support (75%) and funds for supplies and travel.
- Targeting cannabinoid receptors as a novel treatment of breast cancerâ€. American Cancer Society (IRG-100036) Subaward, McKallip (PI) 2003-2004, $15,000.
- The role of CD44 isoforms in endothelial cell damage. Individual National Research Service Award (NIH) F32 HL10455. McKallip (PI) 08/01/2000-11/10/2002, $79,789, PI: Robert McKallip.
- American Association for Cancer Research
- American Association of Immunologists